TNC

Across TCGA pan-cancer cohorts, TNC mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TNC data layer compared with 23 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TNC mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TNC expression acts as an unfavorable survival marker.

PDAC, CCRCC, and LUAD are the cancer types where TNC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.590	0.922	<.001	76	view →
CCRCC	DFS	Median	III,IV	0.399	0.932	.022	16	view →
LUAD	OS	Median	II,III,IV	0.498	0.769	.017	7	view →
HNSC	OS	Tertile	III,IV	0.614	0.799	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TNC–PDAC (OS)

Open the PDAC breakdown →